The transition into a healthcare landscape that rewards value and outcomes over volume presents challenges to traditional CoPay Support/Patient Affordability Programs. We explore some of the implications of our changing healthcare landscape to patient affordability programs; the opportunity for Pharma to deliver value beyond traditional approaches and define what program success should look like in our value-based healthcare landscape.
Success in today’s rapidly changing market access world depends on understanding your product’s value through the eyes of payers and shaping crucial value communication around the needs of market access stakeholders as much as it does on developing solid evidence of the value of your product.
Custom cover wraps align your products with the authority and editorial credibility of America's most-trusted magazine brands.
This targeted and trusted point-of-care marketing solution lets you leverage the waiting room, providing:
• A captive audience that takes action
• Unmatched targeting
• Superior ROI
• Increased confidence to engage doctors
• Turnkey management by a publishing leader
“Cloud software systems that support the complete content lifecycle and incorporate a digital asset management (DAM) solution provide a step-change in digital pharmaceutical marketing. They offer a platform to simplify and accelerate time-to-market processes, comply with regulation and improve productivity.”
TrialCard has a proven track record of successfully transitioning existing patient access and affordability programs while improving the patient experience and growing brands. This case study examines the unique co-pay program design and transition strategy TrialCard developed and executed for a top allergy brand. These improvements helped maximize program impact, resulting in total incremental revenue exceeding 24M.
Pharmaceutical companies face compliance and reporting requirements of the Physicians Payments Sunshine Act of the Affordable Care Act. Many companies are trying to meet these requirements using highly inefficient tools. There is a better way.
As the healthcare landscape moves increasingly toward outcome-based treatment approaches, the need to gather and analyze real-world outcome data has become paramount to gauging medication effectiveness and subsequently recruiting prescribers as brand advocates. This study outlines a feedback program that provides prescribers with patient results of their treatment experience in order to better inform their therapy recommendations. The program is designed to offer a unique value proposition to both patients and physicians to drive increased participation in their treatment.
This report summarizes the results from a recent IDC Health Insights study to identify the top 10 software vendors serving the life science market. The report also breaks out the top 3 vendors serving the four key sub segments that make up the life science enterprise, namely research, development, manufacturing and supply chain, and sales and marketing.
The U.S. Sunshine law has traveled a turbulent road over the past couple of years. Over the course of the 2013-2014 submissions, some best practices have emerged in this dynamic environment. Download this whitepaper to learn eight key best practices for manufacturers to consider in their Sunshine Compliance programs.
The European Medicines Agency (EMA) released the first guidance for biosimilar production in 2005. It facilitated the initial wave of registrations for human growth hormone, epoetin, and filgrastim biosimilars. In the United States, the Biologics Price Competition and Innovation Act of 2009, which became law in 2010, provided an abbreviated biosimilars licensure pathway. It wasn’t until 2012, however, that the FDA issued three draft guidelines intended to bridge the gap and enable a biosimilar program across Europe and the U. S.